GlassScriptPhysician profile
Allison S Roberts
NPI 1508276551
$8,166.25
in general payments reported to CMS, 2019-2025
39 companies · $1,606 in 2025
The $1,606 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $812 · 2022: $2,173 · 2023: $1,730 · 2024: $1,846 · 2025: $1,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,117 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,116.51 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,044.18 | 2021-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $834.29 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $697.76 | 2021-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $647.78 | 2021-2025 | |
| Abbott Laboratories | $625.05 | 2021-2024 | Cardiomems, Ensite |
| Pfizer INC. | $482.86 | 2021-2025 | |
| Medtronic, INC. | $458.65 | 2021-2024 | Corevalve Evolut R, Micra |
| Cvrx, INC. | $383.26 | 2022-2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.35 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $305.39 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $264.90 | 2021-2023 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $226.65 | 2021-2023 | Farxiga, Andexxa |
| Esperion Therapeutics, INC. | $208.59 | 2021-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $187.30 | 2022-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $184.48 | 2022-2024 | Camzyos, Eliquis |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $171.24 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $142.65 | 2022-2024 | |
| Genzyme Corporation | $119.75 | 2021-2024 | |
| Novo Nordisk INC | $109.72 | 2024-2025 | Ozempic |
| Amarin Pharma, INC. | $86.40 | 2022 | |
| G Medical Diagnostic Services, INC. | $85.29 | 2022-2023 | Cardiac Monitoring Suite |
| Sun Pharmaceutical Industries INC. | $64.95 | 2023 | |
| Edwards Lifesciences Corporation | $61.36 | 2025 | Sapien 3 Ultra Resilia |
| Kiniksa Pharmaceuticals International, Plc | $51.20 | 2024 | Arcalyst |
| Boston Scientific Corporation | $49.67 | 2024 | Bodyguardian |
| Recor Medical INC | $38.62 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| Angiodynamics, INC. | $35.34 | 2022 | |
| Abiomed | $34.98 | 2025 | |
| Lilly USA, LLC | $32.09 | 2025 | Zepbound, Mounjaro |
| Cardiva Medical, INC. | $27.48 | 2025 | Savvywire |
| Eisai INC. | $24.18 | 2024 | |
| Innovation Technologies INC | $23.82 | 2023 | Irrisept |
| Lexicon Pharmaceuticals, INC. | $23.07 | 2023 | Inpefa |
| Inari Medical, INC. | $19.37 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Azurity Pharmaceuticals, INC. | $17.25 | 2024 | Edarbyclor |
| Bridgebio Pharma, INC. | $16.70 | 2025 | Attruby |
| Inspire Medical Systems, INC. | $15.20 | 2024 | Inspire |
| Surmodics, INC. | $14.12 | 2024 | Pounce Thrombectomy System, Pounce Venous Thrombectomy System |
| Tactile Systems Technology INC | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.